arXiv (All)
open access
Optimal Biological Dose Combination Finding: A Design Roadmap and Robust Cross-Indication Bayesian Borrowing
Early-phase combination oncology trials increasingly seek the optimal biological dose combination (OBDC) rather than a maximum tolerated dose combination, in line with the FDA's Project Optimus initiative. Existing Bayesian OBDC designs span rule-based, model-assisted, and model-based paradigms, but
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- PK/PD-integrated Bayesian platform design for phase II dose regimen optimization#1078143
- Learning the Maximum Tolerated Dose for Continuous Toxicity via Monotone Bayesian Trees#1078261
- A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)#1138759
- A staggered seamless dose-optimization design for co-developing monotherapy and combination therapy#822368
- Optimizing Cancer Vaccinations Using a Physiologically-Based Pharmacokinetic/Pharmacodynamic (PBPK/PD) Model.#1166991
Record · ID 1049532
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive